Humacyte (HUMA) News Today

Humacyte, Inc. (NASDAQ: HUMA) shares were under pressure as investors weighed a disappointing second-quarter financial performance against encouraging clinical and regulatory developments. The stock remains near its 12-month low, with trading volume substantially above average.

• Positive Sentiment: Humacyte reported strong interim results from the V012 Phase 3 dialysis-access study. Its acellular tissue-engineered vessel (ATEV) produced an average of 91 additional catheter-free days versus an arteriovenous fistula in women and reduced infections to 6 versus 23 per 100 patient-years. The company plans to submit a supplemental Biologics License Application (sBLA) in the second half of 2026, potentially targeting FDA action in May 2027 and a dialysis launch by the end of the second quarter of 2027. Humacyte targets November sBLA filing
• Positive Sentiment: The FDA accepted Humacyte’s investigational new drug application for its coronary tissue-engineered vessel (CTEV), allowing the company to advance a first-in-human Phase 2a study in coronary artery bypass grafting. Humacyte second-quarter business update
• Positive Sentiment: Symvess revenue increased to approximately $0.4 million from $0.1 million a year earlier. Humacyte also raised $57.5 million in a public offering to support commercialization, clinical development and working capital. Humacyte reports clinical and financial progress
• Neutral Sentiment: New commercial and surgical leadership is restructuring Humacyte’s sales, hospital-education and product-adoption efforts. Management said adoption is strengthening, but revenue remains small relative to operating costs. The company also expects approximately $14.3 million in 2026 savings from workforce and operating-cost reductions. Humacyte Q2 earnings call highlights
• Negative Sentiment: Second-quarter adjusted performance disappointed: Humacyte reported a $0.16 per-share loss versus the $0.10 consensus estimate, while revenue of $0.41 million missed expectations of $1.12 million. Humacyte shares fall after Q2 revenue and EPS miss
• Negative Sentiment: Humacyte posted a $36.8 million net loss, while cost of goods sold rose to $1.2 million, including inventory reserves and unused-capacity costs. The results highlight continued cash burn, limited commercial scale and dependence on equity financing, with potential dilution for shareholders. Humacyte reports second-quarter loss